Pfizer Inc. (PFE) — closed signal from December 29, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 29, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published December 29, 2025
Pfizer looks like a short-term trade for income and quick recovery rather than a long-term buy. The stock pays a high dividend near 6.8% which attracts buyers, but the company is currently paying out more than it earns, so the dividend may not last. After heavy recent selling, a bounce is possible, but headlines can cause sudden drops. Treat this as a tactical rebound with strict risk limits.
Primary drivers
- Been sold a lot recently, so a short-term rebound is possible
- Investors move to healthcare in sell-offs, which can lift demand
- High dividend attracts buyers, but payout may not be sustainable
- News about obesity/metabolic drugs keeps the sector in focus
How it played out
PFE: target missed after an 11.2% peak gain
Lyra published PFE on 2025-12-29 at $25.12 as a short-term rebound trade. The thesis expected 12% growth and pointed to recent selling, possible healthcare demand during sell-offs, a high dividend near 6.8%, and obesity and metabolic drug news keeping the sector in focus. It also treated the setup as tactical, with headline risk.
Inside the window from 2025-12-29 to 2026-03-29, PFE rose to a peak of $27.94 on 2026-02-11. That was an 11.2% gain, but it stayed below the $28.13 target. It ended at $27.04. The thesis mostly played out, but the target was not reached.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.